Coya Therapeutics, Inc. (COYA) stock
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/3019% above fair value
$3.09+0.07 (+2.32%)
Close on Nov 18, 2026Market cap $72.48MP/E –Yield –
Coya Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Coya Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$21.83M. For fiscal 2025 it was -$10.74M. The highest annual figure on record is -$3.90M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.74M | – |
| FY2024 | Dec 31, 2024 | -$10.29M | – |
| FY2023 | Dec 31, 2023 | -$11.19M | – |
| FY2022 | Dec 31, 2022 | -$7.24M | – |
| FY2021 | Dec 31, 2021 | -$3.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$7.24M | – |
| Q2 FY2026 | Jun 30, 2026 | -$7.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.01M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.83M | -231.8% |
| Q4 FY2024 | Dec 31, 2024 | -$2.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.56M | – |
| Q1 FY2024 | Mar 31, 2024 | $2.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.59M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.98M | – |
See a number that looks wrong?